The significant survival advantage of female sex in nasopharyngeal carcinoma: A propensity-matched analysis

British Journal of Cancer

Volumn 112, Issue 9, 2015, Pages 1554-1561

  Ouyang, P Y ^a   Zhang, L N ^a   Lan, X W ^a   Xie, C ^b   Zhang, W W ^a   Wang, Q X ^a   Su, Z ^a   Tang, J ^a   Xie, F Y ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Jiangxi Provincial People's Hospital   (China)

Author keywords

nasopharyngeal carcinoma; prognosis; propensity score matching; sex

Indexed keywords

CISPLATIN; FLUOROURACIL; IMMUNOGLOBULIN A; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; MIDDLE AGED; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SEX DIFFERENCE; CHEMORADIOTHERAPY; MORTALITY; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE;

EID: 84928757082     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.70     Document Type: Article

References (27)

1. Austin PC. (2009). The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making 29(6): 661-677
2. Baser O. (2006). Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 9(6): 377-385
3. Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, Gerger A, Benhaim L, Paez D, Wakatsuki T, Loupakis F, El-Khoueiry R, Zhang W, Lenz HJ. (2012). Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol 30(18): 2265-2272
4. Bouman A, Heineman MJ, Faas MM. (2005). Sex hormones and the immune response in humans. Hum Reprod Update 11(4): 411-423
5. Cao SM, Simons MJ, Qian CN. (2011). The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 30(2): 114-119
6. Chang ET, Adami HO. (2006). The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15(10): 1765-1777
7. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. (2012). Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 13(2): 163-171
8. Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ. (2011). Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 103(23): 1761-1770
9. Cheung WY, Shi Q, OConnell M, Cassidy J, Blanke CD, Kerr DJ, Meyers J, Van Cutsem E, Alberts SR, Yothers G, Sargent DJ. (2013). The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33, 345 patients from the ACCENT database. Clin Colorectal Cancer 12(3): 179-187
10. Cox DR. (1972). Regression models and life tables. J R Stat Soc B 34: 187-220
11. DAgostino RB Jr. (1998). Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17(19): 2265-2281
12. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. (2010). AJCC Cancer Staging Handbook from the AJCC Cancer Staging Manual, 7th edn. Springer: New York
13. Ferlay J, Bray F, Pisani P, Parkin DM. (2004). Cancer Incidence, Mortality and Prevalence Worldwide. 2.0, edn. IARC Press: Lyon
14. Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki AG, Karayannopoulou G, Zaramboukas T, Nikolaou A, Markou K, Resiga L, Dionysopoulos D, Samantas E, Athanassiou H, Misailidou D, Skarlos D, Ciuleanu T. (2012). Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol 23(2): 427-435
15. Hidaka H, Hotokezaka M, Nakashima S, Uchiyama S, Maehara N, Chijiiwa K. (2007). Sex difference in survival of patients treated by surgical resection for esophageal cancer. World J Surg 31(10): 1982-1987
16. Huang C, Wu M, Tang Y, Li X, Ouyang J, Xiao L, Li D, Li G. (2009). NAG7 promotes human nasopharyngeal carcinoma invasion through inhibition of estrogen receptor alpha and up-regulation of JNK2/AP-1/MMP1 pathways. J Cell Physiol 221(2): 394-401
17. Joosse A, Collette S, Suciu S, Nijsten T, Patel PM, Keilholz U, Eggermont AM, Coebergh JW, de Vries E. (2013). Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. J Clin Oncol 31(18): 2337-2346
18. Kaplan EL, Meier P. (1958). Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481
19. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J. (2011). How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 80(3): 661-668
20. Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Sham JS, Ngan RK, Law SC, Yau TK, Au JS, OSullivan B, Pang ES, O SK, Au GK, Lau JT. (2005). Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionallyadvanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23(28): 6966-6975
21. Mascitelli L, Goldstein MR. (2013). Explaining sex difference in cancer risk: Might it be related to excess iron? Int J Cancer 133(9): 2261-2262
22. McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, OReilly MS, Cox JD, Allen PK, Komaki R. (2009). Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer? Cancer 115(14): 3233-3242
23. McKinlay SM, Brambilla DJ, Posner JG. (1992). The normal menopause transition. Maturitas 14(2): 103-115
24. Nasr HB, Chahed K, Bouaouina N, Chouchane L. (2008). Functional vascular endothelial growth factor-2578 C/A polymorphism in relation to nasopharyngeal carcinoma risk and tumor progression. Clin Chim Acta 395(1-2): 124-129
25. Schmetzer O, Flörcken A. (2012). Sex differences in the drug therapy for oncologic diseases. In Sex and Gender Differences in Pharmacology, Regitz-Zagrosek V (ed), Vol. 214, Chapter 19, pp 411-442. Springer: Berlin, Heidelberg
26. Xiao G, Cao Y, Qiu X, Wang W, Wang Y. (2013). Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer 13(1): 226
27. Xie SH, Yu IT, Tse LA, Mang OW, Yue L. (2013). Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983-2008: suggestion of a potential protective role of oestrogen. Eur J Cancer 49(1): 150-155